The phase III SUNSHINE and SUNRISE were two identical, multicentre, randomized, placebo-controlled, double-blind phase 3 trials performed in 219 primary sites across 40 countries. With few therapeutic options available for patients with moderate-to-severe hidradenitis suppurativa (HS), Dr Afsaneh Alavi (Mayo Clinic College of Medicine, Rochester, MN, USA) joins touchDERMATOLOGY to discuss the limitations of current therapeutic options for HS, and the clinical utility of secukinumab in the treatment of dermatological diseases. Dr Afsaneh also delves into the two trials and their findings, aimed at assessing the efficacy of secukinumab in patients with moderate-to-severe HS.
Questions:
- What are the limitations of current therapeutic options for hidradenitis suppurativa (HS)? (0:27)
- What is already known about the clinical utility of secukinumab in the treatment of dermatological diseases? (2:29)
- Could you describe the rationale and methodology of the Phase III SUNSHINE and SUNRISE trials? (3:58)
- What were the efficacy and safety findings from these studies? (4:37)
- Following EU approval, what do you believe will be the place of secukinumab in the treatment paradigm for HS? (6:21)
Disclosures: Dr Afsaneh Afsaneh has been a consultant for Abbvie, Almirall, BI, InflaRX, Incyte, Kymera, Janssen, Novartis, and UCB; is on the advisory board for BI, Incyte, Novartis, and UCB; and has received honoraria/honorarium from Abbvie, Almirall, BI, InflaRX, Incyte, Kymera, Janssen, Novartis, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
Click here more content on hidradenitis suppurativa
